U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07516925) titled 'A Study of Ivonescimab in People With Leiomyosarcoma' on April 01.
Brief Summary: The purpose of this study is to find out if Ivonescimab is an effective and safe treatment that causes few or mild side effects for people with advanced/unresectable leiomyosarcoma.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Leiomyosarcoma
Intervention:
DRUG: Ivonescimab
Ivonescimab is administered IV Q3W on Day 1 of each cycle
Recruitment Status: RECRUITING
Sponsor: Memorial Sloan Kettering Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....